Kodiak Sciences Inc. (KOD) Q3 2025 10-Q Quarterly Report
Filed: Nov 13, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Kodiak Sciences Inc. (KOD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 13, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Kodiak Sciences Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: macroeconomic uncertainties including inflation, tariffs, rising interest rates, and bank failures impacting liquidity and operations
- • Updated risk: operational spend increased to $105.9 million for nine months ended Sept 30, 2025, cash used in operating activities $96.6 million vs $87.2 million prior year
- • Compliance risk: no material changes to contractual obligations since 12/31/2024, other than Note 5 financial statement disclosures
- • Market risk: ongoing geopolitical conflicts and supply chain disruptions may materially impact product development timelines
- • Financial risk: cash decreased by $96.0 million in first nine months 2025, requiring continued capital raises for development and commercialization efforts
Get deeper insights on Kodiak Sciences Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.